Featured Clinical Leader Editorial

  1. Digitally Enabled Clinical Trials: A Practical Guide 12/2/2021

    Undoubtedly, digital trials will stay as the world coexists with the pandemic, so it is essential for both sponsors and sites to be early adopters. This article will examine the benefits and challenges of digital clinical trials and identify key considerations for sponsors and sites as the world continues to navigate the new normal.

  2. Digital Vs. Decentralized Trials: What's The Difference & How Do I Meet Implementation Challenges? 11/18/2021

    Digital clinical trials, which have gained momentum since the onset of the pandemic, have the potential to address many of the inefficiencies of traditional trials. This article defines digital clinical trials and how they differ from decentralized clinical trials, as well as how to meet implementation challenges.

  3. Is A Decentralized Clinical Trial Right For Your Trial? & 5 Tips For Success 11/11/2021

    Pharmaceutical companies have achieved considerable success in decentralizing clinical trials and shown that this model can offer significant benefits — both during the pandemic and afterward. While some elements of decentralization can be applied across all trial types, this article covers several specific trial characteristics that are particularly suited to remote studies, as well as tips to maximize success.

  4. How Biopharmas And CROs Can Create Value In Decentralized Global Trials 11/2/2021

    The need for biopharma execs to effectively engage CROs in decentralized clinical trials will only increase in the years to come. This article examines the results of a recent Ernst & Young (EY) study and also offers some recommendations for sponsors and CROs to be more effective with decentralized trials.

  5. Decentralized Clinical Trials: What Are The Opportunities For Data & Cost Savings? 10/19/2021

    Among our industry, sentiment remains positive that decentralized clinical trial models will improve patient centricity and reduce time to market for critical treatments, among other benefits. However, let's take a closer look at this transition to a more decentralized method, focusing in on the opportunities for data and cost savings.

  6. Decentralized Clinical Trials: Does Your Strategy Include These Facets? 9/30/2021

    Decentralized clinical trials have increased in response to the COVID-19 pandemic, yet this may be due to a convergence of two factors already in play: our reliance on the use of digital health technologies and a move by the FDA and industry toward patient-focused, real-world clinical trials that leverage the technological advances already available.

  7. 3 Steps To Getting Your First Decentralized Trial Greenlit & Executed 8/17/2021

    Decentralized trials are complex, yes, but they are just a different kind of complex. Halloran Consulting unpacks the top three strategies to consider before you begin your decentralized trial design and champion your vision to executives.

  8. ICH E6(R3) – Opportunities For Collaborative Alignment Between Stakeholders On eSource & RWE Priorities 12/8/2020

    During the 2020 Avoca Quality and Innovation Summit, an interactive brainstorming system was used during a workshop on ICH E6(R3) to gather industry executives’ insights about guidance that would more rapidly and effectively enable quality adoption of innovative trial designs and technology

  9. A New Patient-Centric Virtual Trial Targets Rare Cancers 10/20/2020

    The TargetCancer Foundation, with support from Bayer, has launched a study to research genomic testing in people with rare cancers. The study, called TRACK (Target Rare Cancer Knowledge), has already enrolled the first patients in the U.S. Those patients have been diagnosed with rare cancers, including those with cancers of unknown primary (CUP). 

  10. Can Virtual Trials Maintain Their Momentum After COVID? 9/17/2020

    Prior to COVID-19, there were many discussions about how it might be possible to conduct virtual trials, using technology and innovative measures. Now that the pandemic has forced many trials into virtual settings, what will it take for the industry to fully implement a virtual approach beyond the pandemic?